All In Biotech

Drug Trial Radar · NCT06863961

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 162 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

162

Actual

Start

Apr 1, 2025

Primary completion

Jul 22, 2026

Study completion Jan 30, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).

Conditions

  • Atopic Dermatitis

Interventions

  • AfimkibartDrug

    Afimkibart will be administered as SC injection.

  • PlaceboDrug

    Placebo will be administered as SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants who Achieve Eczema Area and Severity Index-75 (EASI-75) Response (>= 75% Improvement from Baseline) at Week 16Time frame: Baseline and Week 16

Locations

52 sites in 8 countries. Site status is shown where the registry gives one.

  • First OC Dermatology

    Fountain Valley, California

  • UCLA Division of Dermatology

    Los Angeles, California

  • Dermatology Research Associate

    Los Angeles, California

  • Olympian Clinical Research

    Tampa, Florida

  • Hamilton Research, LLC

    Alpharetta, Georgia

  • Dermatology Affiliates Research Institute, LLC

    Atlanta, Georgia

  • Dawes Fretzin Clinical Res LLC

    Indianapolis, Indiana

  • Southern Indiana Clinical Trials

    New Albany, Indiana

  • Revival Research Institute, LLC

    Troy, Michigan

  • Regents of the University of Minnesota

    Minneapolis, Minnesota

  • Care Access Research - Hoboken

    Hoboken, New Jersey

  • Centricity Research Columbus Dermatology

    Columbus, Ohio

  • Central Sooner Research

    Oklahoma City, Oklahoma

  • Oregon Health & Science University

    Portland, Oregon

  • Best Skin Research LLC

    Camp Hill, Pennsylvania

  • Cumberland Skin Center for Clinical Research LLC

    Hermitage, Tennessee

  • Arlington Research Center

    Arlington, Texas

  • Modern Research Associates

    Dallas, Texas

  • Reveal Research Institute

    Dallas, Texas

  • Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A

    Rio de Janeiro, Brazil

  • Clinica Ibis

    Salvador, Estado de Bahia, Brazil

  • Centro de Estudos em Terapias Inovadoras ? CETI

    Curitiba, Paraná, Brazil

  • Hospital de Clnicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu

    Botucatu, São Paulo, Brazil

  • Centro de Pesquisa São Lucas

    Campinas, São Paulo, Brazil

  • HMCG - Hospital e Maternidade Dr. Christovo da Gama

    Santo Andr, São Paulo, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS

    Sao Jose Rio Preto, São Paulo, Brazil

  • Centre de Recherche Saint-Louis

    Québec, Canada

  • Centricity Research London Victoria

    London, Ontario, Canada

  • DermEffects

    London, Ontario, Canada

  • Lynderm Research Inc

    Markham, Ontario, Canada

  • DermEdge

    Mississauga, Ontario, Canada

  • Hopital Saint Louis

    Cedex 10, Paris, France

  • Dermatologikum Hamburg GmbH

    Hamburg, Germany

  • Klinisches Studienzentrum

    Bad Bentheim, Lower Saxony, Germany

  • DRK Krankenhaus Chemnitz-Rabenstein

    Chemnitz, Saxony, Germany

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Emilia-Romagna, Italy

  • Fondazione IRCCS CA? Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy

  • Azienda Ospedaliero Universitaria Policlinico Gaspare Rodolico - San Marco (Presidio G. Rodolico)

    Catania, Sicily, Italy

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.